Board summary
Key figures
45,577
Registered population
60.6% aged 18–64
16.2%
Aged 65+
ICB 14.9% · England 17.9%
42.5%
In IMD quintile 1
ICB 40.7% · England 21.0%
~16,999
Core20 residents (est.)
Resident basis; registered basis ~20,039 · see page 3
7,168
Hypertension register
+5.37% in 3 yrs · England +5.60%
424
SMI register
11.4% of Salford (LAD)'s
1,248
COPD register
Reviews +0.79% in 3 yrs
Forecast to 2030
8,324
Hypertension patients, 2030
+1,156 on today
70.1%
QRISK ≥20% on statins, 2030
+1.86pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Ten three-year clinical trends trail England.
Over 2023 to 2025, 10 of 25 measures trail England, including learning disability prevalence (-2.6% versus +5.4%) and diabetes statins (-1.4% versus +2.1%).
Scale indicator of unreviewed asthma patients.
Asthma review coverage is 78.7% across 2,987 registered patients, leaving a scale indicator of 637 unreviewed patients that may reflect unverified recall gaps.
Hypertension and diabetes control exceed England.
Hypertension treated to target reaches 80.8% (England 70.3%) and diabetes HbA1c control without frailty reaches 65.2% (England 57.4%) for registered patients.
Population, age and ethnicity
Across 45,577 patients, 23.2% are children, exceeding the England rate of 19.6%
Across 45,577 registered patients, 23.2% (10,565) are aged 0-17, above Salford (LAD) at 21.4%, NHS Greater Manchester Integrated Care Board at 21.8%, and England at 19.6%. Those aged 65+ comprise 16.2% (7,379 patients), versus 14.4% in Salford (LAD), 14.9% in the ICB, and 17.9% in England. Gypsy or Irish Traveller and Roma groups each record 0.1%. Unadjusted dementia prevalence of 0.5% (236 patients) sits below Salford (LAD) at 0.6%, NHS Greater Manchester Integrated Care Board at 0.7%, and England at 0.8%, which may reflect age structure.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Salford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Salford LA) | 2,980 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 91.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 65.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Salford LA) | 1,510 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Salford LA) | 15.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 42.5% across the PCN and varies 100 pp across practices
Registered patients in the Core20 cohort make up 42.5% of the PCN, below Salford (LAD) at 44.0%, but above NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). The weighted practice share of 44.0% exceeds the PCN rate by 1.50 percentage points. Practice concentration spans 100 pp, from 0.0% at Ellenbrook Medical Centre and Orchard Medical Practice to 100.0% at Dearden Avenue Medical Practice, while Cleggs Lane Medical Practice/129 holds 4,926 estimated Core20 patients. Resource allocation should address high concentration alongside absolute volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
424
SMI register
0.94% recorded prevalence
272
Learning disability register
0.60% recorded prevalence
7
Care homes, 276 beds
In the PCN catchment
9.2%
Provide unpaid care
Salford (LAD), Census 2021
The severe mental illness register records 424 patients (0.9%), below Salford (LAD) (1.1%), the ICB (1.1%) and England (1.0%). The learning disability register records 272 patients (0.6%), above Salford (LAD) (0.5%) and matching the ICB (0.6%) and England (0.6%). Care home catchment includes 7 homes with 276 beds.
Severe mental illness: physical health checks
Severe mental illness recorded prevalence is 0.9% (424 patients). Blood pressure checks reach 91.1% (England 83.4%) and BMI checks reach 91.4% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,168
Hypertension register
+5.37%
Register growth, 3 yrs
Salford (LAD) +5.45% · England +5.60%
+5.50pp
BP control, under 80
≤140/90 · +1.99pp aged 80+
+1,156
More patients by 2030
Forecast 8,324 (17.69%)
Hypertension case-finding and control
Recorded hypertension prevalence is 15.9% (7,168 patients), above Salford (LAD) (12.4%), NHS Greater Manchester Integrated Care Board (14.4%), and England (15.2%). Blood pressure treated to target is 80.8%, exceeding Salford (LAD) (77.6%), the ICB (71.4%), and England (70.3%). Recent blood pressure reading coverage is 94.4% (England 90.0%), though three-year reading growth of +3.2% trails England (+3.6%) and Salford (LAD) (+4.6%). Across practices, recorded prevalence spans from 12.2% at Dearden Avenue Medical Practice and 12.4% at Cleggs Lane Medical Practice/129 to 18.4% at The Gill Medical Practice. Trailing three-year reading growth could reflect established baseline coverage; audits across lower-prevalence practices may help test local recording.
Lipids and statins
Lipid therapy reach is 66.2% for QRISK ≥ 20% (England 63.6%) and 78.5% in diabetes without CVD (England 73.2%). Over 2023 to 2025, treatment changes trailed England in diabetes (-1.4% versus +2.1%) and QRISK ≥ 20% (+2.9% versus +6.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 94,483 | £1.60 | £1.94 | £1.86 | £151,173 |
| Cardiovascular (all), 2025 | 129,930 | £2.44 | £3.15 | £3.33 | £317,029 |
In 2026, the PCN prescribed 94,483 lipid-regulating drug items at £1.60 per item, compared with £1.54 in Salford (LAD), £1.94 in NHS Greater Manchester Integrated Care Board, and £1.86 in England. Across these 94,483 items, the PCN spent £24,566 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.75%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.20%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 2.8% (1,248 patients; England 1.9%), with reviews at 84.0% (England 76.4%), though 2023 to 2025 review change of +0.8% trailed Salford (LAD) (+12.2%). Asthma prevalence is 7.2% (2,987 patients; England 6.6%), where 78.7% had an annual review (England 65.7%). This leaves an unreviewed scale indicator of 637 patients (about 640). Asthma prescribing for ages 5-19 is 1,752 items per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer QOF prevalence is 3.7% (1,670 patients; England 3.8%). Childhood immunisations reach the 95.0% coverage target for 6-in-1 at 12 months (95.8%) and MMR dose 1 at age 5 (95.5%). MMR dose 2 coverage at age 5 is 90.3% (a 5.2 pp difference from dose 1), while 4-in-1 pre-school booster coverage at age 5 is 86.4%, sitting 8.6 pp below the 95.0% coverage target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), with a distance to the 75.0% national ambition by 2028 of -19.4 pp. Known-stage cancers represented 70.8% of all 16,492 registrations (England 67.0%). The ICB early-stage share rose +3.1 pp from 52.4% in 2013, leaving an estimated gap of about 2,270 additional early diagnoses annually across the system to achieve the ambition. These figures describe wider ICB staging rather than PCN performance. Primary care contribution centres on prompt referral and screening uptake to support earlier presentation across system pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Northern Care Alliance NHS Foundation Trust, the distance to the 85.0% 62-day cancer referral to treatment standard is -6.4 pp, the distance to the 75.0% 28-day faster diagnosis standard is 0.2 pp, and the distance to the 96.0% 31-day combined treatment standard is -1.5 pp. Across NHS Greater Manchester Integrated Care Board, the distance to the 62-day standard is -9.3 pp, the distance to the 28-day standard is 4.5 pp, and the distance to the 31-day standard is 0.5 pp. These figures describe acute trust and ICB performance rather than PCN delivery.
| Pathways within standard (%) | Northern Care Alliance | Bolton | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.50 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 69.66 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Bolton | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 2.05 | 11.68 | 21.40 |
| CT | 4.10 | 19.40 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 3.48 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.33 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 2.06 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 15.78 | 8.98 | 23.14 |
| Community services activity | Salford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 37,955 | 573,310 |
| Referrals | 3,340 | 94,470 |
| Patients with a contact | 15,440 | 183,535 |
Community services (residents of Salford), Jun 2026 (provisional). In the Community Services Dataset (Jun 2026 (provisional)), adults aged 65 and over accounted for 53.9% of all contacts among Salford residents (20,470 of 37,955 contacts). These borough-level figures demonstrate substantial older-age community caseload demand, though activity was not captured at PCN level.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, England clinical-domain achievement was 97.1%. QOF clinical achievement reached 96.8% at Ellenbrook Medical Centre and 100.0% at The Gill Medical Practice. In the vaccination and immunisation domain, achievement ranged 55.3 pp, from 15.6% at Dearden Avenue Medical Practice and The Limes Medical Practice to 70.9% at Cleggs Lane Medical Practice/129.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Gill Medical | 128 | 37.5 | 81.0% | 79.9% | 88.1% |
| Cherry Medical | 86 | 95.7 | 91.1% | 81.9% | 86.3% |
| Ellenbrook | 143 | 0.0 | 62.1% | 71.2% | 85.2% |
| Cleggs Lane | 123 | 95.3 | 73.5% | 75.6% | 84.5% |
| Dearden Avenue | 105 | 100.0 | 77.8% | 72.4% | 83.7% |
| Manchester Road | 100 | 88.7 | 91.0% | 77.3% | 83.3% |
| Limes Medical | 112 | 21.9 | 72.2% | 81.9% | 81.8% |
| Orchard Medical | 106 | 0.0 | 88.5% | 80.0% | 79.4% |
| Walkden | 142 | 27.4 | 64.9% | 72.8% | 63.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
10 of 25 measures trail England over three years despite high clinical control
Over 2023 to 2025, 10 of 25 compared measures trail England's three-year change. The widest relative lags are learning disability prevalence, which fell 2.6% (England +5.4%), though recorded prevalence matches England at 0.6%, and heart failure reviews, which rose +1.8% (England +8.7%). Heart failure review reach remains 86.6% against 78.5% in England. Strengths include diabetes HbA1c control without frailty, rising +12.9% over 2023 to 2025 (England +4.4%), reaching 65.2% against 57.4% in England. Slower review growth could reflect ceiling effects on established high baseline reach.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
Diabetes statin (no CVD)
QRISK statin treatment
Asthma register
Diabetes HbA1c control
Asthma reviews
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Salford (LAD) | Asset | PCN | Salford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (276 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 4 | 16 | Places of worship | 19 | 118 |
| Libraries | 3 | 16 | Primary schools (LA maintained) | 15 | 52 |
| Primary academies | 4 | 21 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Audit trailing register and statin trends
Over 2023 to 2025, 10 of 25 measures trail England, including learning disability prevalence (-2.6% versus +5.4%) and statins in diabetes without CVD (-1.4% versus +2.1%). For discussion: practices could audit learning disability register coding and run recall searches for high-risk lipid and heart failure reviews. Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 2
Structured recall for unreviewed asthma patients
Asthma annual review coverage is 78.7% (England 65.7%; Salford (LAD) 71.6%) across 2,987 registered patients, leaving a scale indicator of 637 unreviewed patients. For discussion: the PCN could run structured asthma review recalls using a single template and flexible after-school or holiday slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Dementia coding and case-finding review
Recorded dementia prevalence is 0.5% (236 patients) versus 0.6% in Salford (LAD) and 0.8% in England, giving an unadjusted gap range of +47 to +121 patients. For discussion: practices could audit cognitive assessment coding and check care-home records to verify whether patients with diagnoses are coded. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dementia case finding audit (p2) | Registered population · Aged 0-17 | Neighbourhood health framework · Medium Term Planning Framework 2026 | PCN |
| Two-track Core20 outreach model (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustain SMI health check delivery (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall review (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early diagnosis pathway audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Audit trailing register and statin trends (p12) | Learning disability register · Learning disability: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 2 · Structured recall for unreviewed asthma patients (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Dementia coding and case-finding review (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
